2. Parsonnet J, Hansen S, Rodriguez L, et al.
Helicobacter pylori infection and gastric lymphoma. N Engl J Med 1994;330:1267-1271.
3. Wotherspoon AC, Ortiz-Hidalgo C, Falzon MR, Isaacson PG.
Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma. Lancet 1991;338:1175-1176.
4. Ruskoné-Fourmestraux A, Fischbach W, Aleman BM, et al.; EGILS group. EGILS consensus report. Gastric extranodal marginal zone B-cell lymphoma of MALT. Gut 2011;60:747-758.
5. Zucca E, Copie-Bergman C, Ricardi U, Thieblemont C, Raderer M, Ladetto M.; ESMO Guidelines Working Group. Gastric marginal zone lymphoma of MALT type: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013;24 Suppl 6:vi144-vi148.
6. Zullo A, Hassan C, Andriani A, et al. Eradication therapy for
Helicobacter pylori in patients with gastric MALT lymphoma: a pooled data analysis. Am J Gastroenterol 2009;104:1932-1937; quiz 1938.
7. Zullo A, Hassan C, Ridola L, et al. Eradication therapy in
Helicobacter pylori-negative, gastric low-grade mucosa-associated lymphoid tissue lymphoma patients: a systematic review. J Clin Gastroenterol 2013;47:824-827.
8. Zelenetz AD, Gordon LI, Chang JE, et al. NCCN guidelines® insights: B-cell lymphomas, version 5.2021. J Natl Compr Canc Netw 2021;19:1218-1230.
9. Nakamura S, Sugiyama T, Matsumoto T, et al.; JAPAN GAST Study Group. Long-term clinical outcome of gastric MALT lymphoma after eradication of
Helicobacter pylori: a multicentre cohort follow-up study of 420 patients in Japan. Gut 2012;61:507-513.
11. Tahara T, Horiguchi N, Terada T, et al.
H. pylori negative gastric MALT lymphoma with API2-MALT1 translocation treated by endoscopic submucosal dissection: a case report. Medicine (Baltimore) 2021;100:e24371.
12. Copie-Bergman C, Wotherspoon AC, Capella C, et al. Gela histological scoring system for post-treatment biopsies of patients with gastric MALT lymphoma is feasible and reliable in routine practice. Br J Haematol 2013;160:47-52.
15. Kahl BS. Update: gastric MALT lymphoma. Curr Opin Oncol 2003;15:347-352.
18. Lehours P, Ruskone-Fourmestraux A, Lavergne A, Cantet F, Mégraud F.; Groupe d'Etude des Lymphomes Digestifs (GELD) for the Fédération Française de Cancérologie Digestive (FFCD). Which test to use to detect
Helicobacter pylori infection in patients with low-grade gastric mucosa-associated lymphoid tissue lymphoma? Am J Gastroenterol 2003;98:291-295.
20. Raderer M, Wöhrer S, Streubel B, et al. Assessment of disease dissemination in gastric compared with extragastric mucosa-associated lymphoid tissue lymphoma using extensive staging: a single-center experience. J Clin Oncol 2006;24:3136-3141.
21. Gong EJ, Ahn JY, Jung HY, et al. Bone marrow involvement is not associated with the clinical outcomes of gastric mucosa-associated lymphoid tissue lymphoma. Scand J Gastroenterol 2016;51:942-948.
22. Won D, Park CJ, Shim H, et al. Subtle CD20 positivity in the bone marrow of a patient who has a mucosa-associated lymphoid tissue lymphoma should not be regarded as evidence of involvement in the bone marrow. Histopathology 2013;62:397-405.
23. Zucca E, Arcaini L, Buske C, et al.; ESMO Guidelines Committee. Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2020;31:17-29.
24. Wirth A, Gospodarowicz M, Aleman BM, et al. Long-term outcome for gastric marginal zone lymphoma treated with radiotherapy: a retrospective, multi-centre, International Extranodal Lymphoma Study Group study. Ann Oncol 2013;24:1344-1351.
25. Goda JS, Gospodarowicz M, Pintilie M, et al. Long-term outcome in localized extranodal mucosa-associated lymphoid tissue lymphomas treated with radiotherapy. Cancer 2010;116:3815-3824.